Mark Dresser, PhD
Anuradha Ramamoorthy, PhD
Scientific Program Committee Chair
Abstract submissions are now closed for the ASCPT 2023 Annual Meeting.
ASCPT 2023 Abstract Fees
Please note abstract fees are non-refundable. ASCPT will not refund the difference for an incorrect submission type selection.
*In order to qualify for the member rate, at least one author on the abstract must have an active ASCPT membership at the time of submission.
Abstract Submission Details
All abstracts must:
Late-Breaking abstracts must
- Address a clinical, translational, or methodology-based question.
- Apply to clinical pharmacology or translational science.
- Describe original, previously unpublished work.
- Identify the primary ASCPT Community related to the content of the abstract. (https://www.ascpt.org/Member-Services/Networks-and-Communities)
- Obtain management approval prior to submitting the abstract, if management approval is required from your institution. If the abstract is withdrawn after acceptance for reasons such as lack of management approval, you will be barred from submitting an abstract to ASCPT for a period of one (1) year.
All Encore abstracts must
- Include data that could not be analyzed before September 15, 2022, due to unavailability of the data.
- Present significant, ground-breaking, and innovative data.
- Describe original, previously unpublished work
Trial in Progress Abstract Submissions must:
- Present significant, ground-breaking, and innovative findings that were published (in paper or online) as an original research article in a peer-reviewed journal on or after January 1, 2022, and address a question of relevance to clinical pharmacology and therapeutics.
- The January 1, 2022, cut-off for earliest publication date refers to the first date of publication (e.g., online electronic publication of the accepted article). The citation to this publication needs to be included in the submission.
- Encore submissions based on findings previously presented solely in abstract form (e.g., as published in conference proceedings) that are not yet published as an original research article in a peer-reviewed journal do not qualify for submission.
- Adhere to all submission guidelines of regular abstract submission with the primary difference being that no results should be reported.
- Be organized into three sections:
- Scientific background/rationale for the trial
- Trials in Progress abstract submissions should not be used to present preclinical or earlier-phase clinical data for the first time. Preclinical and earlier-phase data that have been published can be included as a reference.
- Trial design and statistical methods, highlighting any novel aspects of the design.
- Major eligibility criteria without providing results or endpoints.
- Treatment or intervention planned.
- Major eligibility criteria, highlighting unusual aspects.
- Current enrollment without results or endpoints
- Phase I studies may refer to “Cohort 1 and 2” etc.
- Phase II studies may refer to “x of X patients have been enrolled” etc.
- Phase III studies may refer to “The IRB last reviewed the trial in Month/Year and recommended that the trial continue as planned.”
- Patient enrollment must have begun or completed with no data analysis available by the abstract submission deadline. Exceptions will not be made to this criterion. Trials for which patients have not yet been enrolled will be considered.
- The clinical trial registry number must be included in the abstract.
- Novelty of Design
- How might this change clinical pharmacology or translational science?
- Abstract Title: Title case; 75 words maximum.
- Body: 1,550 characters count, not including spaces. Do not include title, author, or institution information.
Authorship requires that an individual has contributed in one of the following ways:
At the time of submission, the submitting author must know the following information for all authors:
- Wrote the paper
- Designed/performed the research
- Analyzed data
- Contributed new reagents or analytical tools
Table or Figures:
There is a 400-character penalty for including a table or figure.
- Author name & email
- Author institution
- Authors’ Conflicts of Interest
You will be required to upload 2 file types for included tables or figures (PDF or EPS file and JPG or PNG file).
ASCPT encourages all poster presenters to utilize the Poster 2.0 format developed by Mike Morrison. A prize will be award to the selected Best of Poster 2.0s at the 2023 Annual Meeting. Examples of the Best of Poster 2.0 awardees from ASCPT 2022 Annual Meeting can be found here
Accepted abstracts will be published in the Abstract Supplement to Clinical Pharmacology & Therapeutics. Please be sure to review your submission thoroughly – the abstracts will be published exactly as they are submitted. ASCPT will not edit abstracts
In consideration of the Society evaluating the Contribution for publication (and publishing the Contribution if the Society so decides) the Author(s) grant to the Society for the full term of copyright and any extensions thereto, subject to clause 2 below, the exclusive right and irrevocable license:
- to edit, adapt, publish, reproduce, distribute, display, and store the Contribution in all forms, formats, and media whether now known or hereafter developed (including without limitation in print, digital and electronic form) throughout the world;
- to license others to do any or all of the above.
Ownership of copyright remains with the Author(s).
Academic institutions, private organizations, and companies with products whose values may be influenced by information contained in an abstract may issue a press release to coincide with the abstract’s publication. However, information beyond that contained in the abstract, e.g., discussion of the abstract done as part of a scientific presentation or presentation of additional or new information that will be available at the time of the meeting, is embargoed until the start of the ASCPT 2023 Annual Meeting. To assist in the promotion of abstracts prior to the Annual Meeting, ASCPT will publish all abstract numbers, titles, and author details online as part of the scientific program prior to publication of the CPT supplement.
Information released prior to this day is a violation of the ASCPT Abstract Embargo Policy and may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy.
Questions can be directed to email@example.com or (703) 836-6981, extension 108.